PURPOSE: Na,K-adenosine triphosphatase, which is composed of a catalytic alpha-subunit and a regulatory beta-subunit, generates an electrochemical gradient across the plasma membrane. Previous studies demonstrated altered Na,K-adenosine triphosphatase subunit expression in renal clear cell carcinoma and an association of subunit levels with the prediction of recurrent bladder cancer. We determined the clinical association of protein expression patterns of the Na,K-adenosine triphosphatase alpha1 and beta1-subunits in renal clear cell carcinoma using tissue microarrays with linked clinicopathological data. MATERIALS AND METHODS: The UCLA kidney cancer tissue microarray was used to investigate the protein expression of Na,K-adenosine triphosphatase alpha1 and beta1-subunits by immunohistochemistry in 342 patients with renal clear cell carcinoma who were treated with radical nephrectomy. Of these patients clinical outcomes studies were performed in 317. The resultant expression reactivity was correlated with clinicopathological variables. RESULTS: We found that the alpha1-subunit was a significant and independent predictor of disease specific death from renal clear cell carcinoma on multivariate Cox proportional hazards analysis that included established prognostic factors Eastern Cooperative Oncology Group performance status, pT status, metastasis status and tumor grade. Significance was found when examining all patients with clear cell renal cell carcinoma as well as patient substrata with low or high grade tumors and localized or metastatic disease, suggesting that the Na,K-adenosine triphosphatase alpha1-subunit could be used as a new prognosticator for disease specific death from renal clear cell carcinoma. CONCLUSIONS: These results suggest that Na,K-adenosine triphosphatase alpha1-subunit expression patterns may be a useful clinical prognosticator for renal clear cell carcinoma. The Na,K-adenosine triphosphatase beta1-subunit was not found to be a useful prognosticator in this setting.
PURPOSE: Na,K-adenosine triphosphatase, which is composed of a catalytic alpha-subunit and a regulatory beta-subunit, generates an electrochemical gradient across the plasma membrane. Previous studies demonstrated altered Na,K-adenosine triphosphatase subunit expression in renal clear cell carcinoma and an association of subunit levels with the prediction of recurrent bladder cancer. We determined the clinical association of protein expression patterns of the Na,K-adenosine triphosphatase alpha1 and beta1-subunits in renal clear cell carcinoma using tissue microarrays with linked clinicopathological data. MATERIALS AND METHODS: The UCLA kidney cancer tissue microarray was used to investigate the protein expression of Na,K-adenosine triphosphatase alpha1 and beta1-subunits by immunohistochemistry in 342 patients with renal clear cell carcinoma who were treated with radical nephrectomy. Of these patients clinical outcomes studies were performed in 317. The resultant expression reactivity was correlated with clinicopathological variables. RESULTS: We found that the alpha1-subunit was a significant and independent predictor of disease specific death from renal clear cell carcinoma on multivariate Cox proportional hazards analysis that included established prognostic factors Eastern Cooperative Oncology Group performance status, pT status, metastasis status and tumor grade. Significance was found when examining all patients with clear cell renal cell carcinoma as well as patient substrata with low or high grade tumors and localized or metastatic disease, suggesting that the Na,K-adenosine triphosphatase alpha1-subunit could be used as a new prognosticator for disease specific death from renal clear cell carcinoma. CONCLUSIONS: These results suggest that Na,K-adenosine triphosphatase alpha1-subunit expression patterns may be a useful clinical prognosticator for renal clear cell carcinoma. The Na,K-adenosine triphosphatase beta1-subunit was not found to be a useful prognosticator in this setting.
Authors: Sigrid A Rajasekaran; Thu P Huynh; Daniel G Wolle; Cromwell E Espineda; Landon J Inge; Anna Skay; Charles Lassman; Susanne B Nicholas; Jeffrey F Harper; Anna E Reeves; Mansoor M Ahmed; James M Leatherman; James M Mullin; Ayyappan K Rajasekaran Journal: Mol Cancer Ther Date: 2010-05-25 Impact factor: 6.261
Authors: Thu P Huynh; Vei Mah; Valerie B Sampson; David Chia; Michael C Fishbein; Steve Horvath; Mohammad Alavi; Debbie C Wu; Jeffrey Harper; Ted Sarafian; Steven M Dubinett; Sigrid A Langhans; Lee Goodglick; Ayyappan K Rajasekaran Journal: Am J Physiol Lung Cell Mol Physiol Date: 2012-02-17 Impact factor: 5.464
Authors: Utibe-Abasi S Udoh; Moumita Banerjee; Pradeep K Rajan; Juan D Sanabria; Gary Smith; Mathew Schade; Jacqueline A Sanabria; Yuto Nakafuku; Komal Sodhi; Sandrine V Pierre; Joseph I Shapiro; Juan R Sanabria Journal: Int J Mol Sci Date: 2022-07-01 Impact factor: 6.208
Authors: Laetitia Moreno Y Banuls; Adriana Katz; Walter Miklos; Alessio Cimmino; Daniel M Tal; Elena Ainbinder; Martin Zehl; Ernst Urban; Antonio Evidente; Brigitte Kopp; Walter Berger; Olivier Feron; Steven Karlish; Robert Kiss Journal: Mol Cancer Date: 2013-04-26 Impact factor: 27.401
Authors: Véronique Mathieu; Christine Pirker; Elisabeth Martin de Lassalle; Mathieu Vernier; Tatjana Mijatovic; Nancy DeNeve; Jean-François Gaussin; Mischael Dehoux; Florence Lefranc; Walter Berger; Robert Kiss Journal: J Cell Mol Med Date: 2009-02-20 Impact factor: 5.310